New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
November 11, 2012
19:56 EDTHZNPHorizon presents data showing effectiveness of RAYOS
Horizon Pharma announced an additional analysis of data from the pivotal Circadian Administration of Prednisone in Rheumatoid Arthritis-2, CAPRA-2, clinical trial demonstrating that patients with active rheumatoid arthritis (RA) treated with its recently approved RAYOS 5 mg (prednisone) delayed-release tablets had a significant improvement in reduction of fatigue, as determined by the Functional Assessment of Chronic Illness Therapy - Fatigue, FACIT-F, questionnaire. Data were presented during the American College of Rheumatology, ACR/Association of Rheumatology Health Professionals,ARHP, Annual Scientific Meeting in Washington, D.
News For HZNP From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 17, 2014
07:45 EDTHZNPHorizon Pharma to host conference call
Subscribe for More Information
07:04 EDTHZNPHorizon Pharma acquires U.S. rights to PENNSAID 2% for $45M
Subscribe for More Information
October 13, 2014
17:06 EDTHZNPHorizon Pharma: Actimmune net sales potential $500M with FDA approval for FA
Subscribe for More Information
05:31 EDTHZNPHorizon Pharma to host analyst day
Analyst Day to be held in King of Prussia, PA on October 13 at 5 pm. Webcast Link
October 9, 2014
15:31 EDTHZNPHorizon Pharma's Actimmune Phase 2 results provide more growth, says Avondale
Avondale said Horizon Pharma's Actimmune Phase 2 results were strong and support incremental annual market opportunity of approximately $300K per year. The firm views the results as another potential growth driver and its Outperform rating and $22 price target.
13:40 EDTHZNPHorizon Pharma presents ACTIMMUNE Phase 2 data
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use